ZL-2306(nirapairb)

Phase 3Small molecule

ZZai Lab (Shanghai) Co., Ltd.

ZL-2306(nirapairb) is one of 65 small molecule programs targeting Ovarian Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Ovarian CancerActive, not recruiting

Small Cell Lung CancerActive, not recruiting

Ovarian CancerPhase 3

Active, not recruiting

Small Cell Lung CancerPhase 3

Active, not recruiting

Competition

Competitive Landscape

836 competitors in Ovarian Cancer

#DrugCompanyPhaseTrials

Perjeta

Roche

Phase 3

3 2

Taxotere

AAvyxa

Phase 3

11 3

Jemperli

GGlaxo Dba Glaxosmithkline

Phase 3

4 4

Tylenol

KKenvue Brands

Phase 3

1 5

Taxane

Bristol-Myers Squibb

Phase 3

2 6

Trastuzumab Deruxtecan

AstraZeneca

Phase 3

1 7

Apatinib Mesylate

BBukwang Pharmaceutical

Phase 3

3 8

Salvage Chemotherapy

Daiichi Sankyo

Phase 3

1 9

Masitinib

AAB Science

Phase 3

1 10

Anlotinib Hydrochloride

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Ovarian Cancer3 trials

Clinical Trial Evaluating the Efficacy and Safety of ZL-2306 (Niraparib) in Ovarian Cancer Patient

Unknown status·ZZai Lab (Shanghai) Co., Ltd.·Phase 3·NCT03705156·265 enrolled

A Study of ZL-2306 (Niraparib) as Maintenance Treatment Following First-line Chemotherapy in Patients With Advanced Ovarian Cancer

Unknown status·ZZai Lab (Shanghai) Co., Ltd.·Phase 3·NCT03709316·384 enrolled

The Clinical Trial to Evaluate the Pharmacokinetics, Safety and Tolerability of ZL-2306 (Niraparib) in Patients With Ovarian Cancer

Completed·ZZai Lab (Shanghai) Co., Ltd.·Phase 1·NCT03551171·42 enrolled

Small Cell Lung Cancer1 trial

A Study of Niraparib as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Patients With Extensive Stage Small Cell Lung Cancer

Terminated·ZZai Lab (Shanghai) Co., Ltd.·Phase 3·NCT03516084·185 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for ZL-2306(nirapairb). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ZL-2306(nirapairb) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ZL-2306(nirapairb). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Zai Lab (Shanghai) Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: ZZai Lab (Shanghai) Co., Ltd.

ZL-2306(nirapairb)

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Ovarian Cancer3 trials

Small Cell Lung Cancer1 trial

References

Drug Info

Quick Facts

Related News